Confirmation of Change in ADS Ratio
AstraZeneca PLC (the "Company") today confirmed that the intended ratio change to its NYSE-listed sponsored Level 2 American Depositary Receipt ("ADR") programme announced on 26 June 2015 has now become effective. With effect from 27 July 2015, the Company's American Depositary Share ("ADS") ratio is two (2) ADSs per one (1) Ordinary Share. The former ratio was one (1) ADS per one (1) Ordinary Share. There are no changes to the underlying Ordinary Shares.
ADS holders at the close of business New York time on the record date, 22 July 2015, received a distribution of one additional ADS for every ADS held. No action was required by ADS holders to effect this change.
Contact details for Citibank, N.A., the Company's ADR depositary, can be found below.
A C N Kemp
Company Secretary
27 July 2015
CONTACT
Citibank Shareholder Services
| PO Box 43077 Providence RI 02940-3077 US |
Tel (toll free in the US): +1-888-697-8018 Tel (outside the US): +1-781-575-4555 |
Media Enquiries
| Esra Erkal-Paler | +44 20 7604 8030 (UK/Global) |
| Jacob Lund | +46 8 553 260 20 (Sweden) |
| Michele Meixell | + 1 302 885 6351 (US) |
Investor Enquiries
| UK | |||
| Thomas Kudsk Larsen | +44 20 7604 8199 | mob: +44 7818 524185 | |
| Eugenia Litz | Respiratory, Inflammation and Autoimmunity | +44 20 7604 8233 | mob: +44 7884 735627 |
| Nick Stone | Cardiovascular andMetabolic Disease | +44 1763 263 994 | mob: +44 7717 618834 |
| Karl Hård | Oncology | +44 20 7604 8123 | mob: +44 7789 654364 |
| Craig Marks | Infection, Neuroscience and Gastrointestinal Disease | +44 20 7604 8591 | mob: +44 7881 615764 |
| Christer Gruvris | +44 20 7604 8126 | mob: +44 7827 836825 | |
| US | |||
| Dial / Toll-Free | 301-398-3251 | 866-381-7277 |